Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 May;31(5):327-338.
doi: 10.1016/j.jtct.2025.02.019. Epub 2025 Mar 1.

T Cell Immune Response to Influenza Vaccination When Administered Prior to and Following Autologous Chimeric Antigen Receptor-Modified T Cell Therapy

Hannah Kinoshita  1 , Carla S Walti  2 , Kathleen Webber  3 , Gloria Pezzella  3 , Mariah Jensen-Wachspress  3 , Haili Lang  3 , Kiel Shuey  4 , Jim Boonyaratanakornkit  5 , Steven A Pergam  6 , Helen Y Chu  4 , Catherine M Bollard  1 , Michael D Keller  1 , Joshua A Hill  7
Affiliations

T Cell Immune Response to Influenza Vaccination When Administered Prior to and Following Autologous Chimeric Antigen Receptor-Modified T Cell Therapy

Hannah Kinoshita et al. Transplant Cell Ther. 2025 May.

Abstract

Chimeric antigen receptor-modified T (CAR-T) cell therapies are gaining wider use in relapsed and refractory malignancies. However, data on vaccination in this population is lacking. We evaluated T cell responses in an established cohort of CAR-T recipients and healthy controls before and after 2019 to 2020 influenza vaccination. Peripheral blood mononuclear cells were isolated from healthy controls and patients who received the 2019 to 2020 influenza vaccine pre- or post-CD19, CD20, or B cell maturation antigen CAR-T. T cells were expanded in vitro for 10 days with peptide libraries for hemagglutinin (HA) and nucleoprotein from the 2019 to 2020 vaccine influenza A strains and analyzed by flow cytometry following interferon-γ/tumor necrosis factor-α (IFNγ/TNFα) intracellular staining. Antibody response was evaluated by a hemagglutination inhibition assay. Twenty-nine participants, including eight immunocompetent adults, seven pre-CAR-T, and 14 post-CAR-T patients, were evaluated. IFNγ+/TNFα+ T cell responses after influenza vaccination in healthy controls varied with an increased response to HA-Kansas after vaccination in 7/8 individuals. In the pre-CAR-T cohort, there was a rise in CD4+ T cell response to HA-Brisbane in 6/7 patients after vaccination that remained detectable in 3/4 evaluable patients 90 days post-CAR-T. Five of six patients who lacked an antibody response nonetheless demonstrated a T cell response to HA-Brisbane. There was no association between time since CAR-T administration, baseline immunoglobulin G, or absolute lymphocyte count and change in CD4+ T cell IFNγ+/TNFα+ response pre- to postvaccine for the post-CART cohort. These data demonstrate that cell-mediated immunity to the influenza vaccine can be elicited in patients vaccinated pre-CAR-T and sustained post-CAR-T, filling an important gap from lack of humoral responses.

Keywords: CAR-T; Cellular Immunity; Immunotherapy; Influenza; Vaccine.

PubMed Disclaimer

References

    1. Baird JH, Epstein DJ, Tamaresis JS, Ehlinger Z, Spiegel JY, Craig J, Claire GK, Frank MJ, Muffly L, Shiraz P, Meyer E, Arai S, Brown JW, Johnston L, Lowsky R, Negrin RS, Rezvani AR, Weng WK, Latchford T, Sahaf B, Mackall CL, Miklos DB, Sidana S. Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma. Blood Adv. 2021. Jan 12;5(1):143–155. doi: 10.1182/bloodadvances.2020002732. - DOI - PMC - PubMed
    1. Logue JM, Zucchetti E, Bachmeier CA, Krivenko GS, Larson V, Ninh D, Grillo G, Cao B, Kim J, Chavez JC, Baluch A, Khimani F, Lazaryan A, Nishihori T, Liu HD, Pinilla-Ibarz J, Shah BD, Faramand R, Coghill AE, Davila ML, Dholaria BR, Jain MD, Locke FL. Immune reconstitution and associated infections following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma. Haematologica. 2021. Apr 1;106(4):978–986. doi: 10.3324/haematol.2019.238634. - DOI - PMC - PubMed
    1. Park JH, Romero FA, Taur Y, Sadelain M, Brentjens RJ, Hohl TM, Seo SK. Cytokine Release Syndrome Grade as a Predictive Marker for Infections in Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia Treated With Chimeric Antigen Receptor T Cells. Clin Infect Dis. 2018. Aug 1;67(4):533–540. doi: 10.1093/cid/ciy152. - DOI - PMC - PubMed
    1. Beck CR, McKenzie BC, Hashim AB, Harris RC, Zanuzdana A, Agboado G, Orton E, Béchard-Evans L, Morgan G, Stevenson C, Weston R, Mukaigawara M, Enstone J, Augustine G, Butt M, Kim S, Puleston R, Dabke G, Howard R, O’Boyle J, O’Brien M, Ahyow L, Denness H, Farmer S, Figureroa J, Fisher P, Greaves F, Haroon M, Haroon S, Hird C, Isba R, Ishola DA, Kerac M, Parish V, Roberts J, Rosser J, Theaker S, Wallace D, Wigglesworth N, Lingard L, Vinogradova Y, Horiuchi H, Peñalver J, Nguyen-Van-Tam JS. Influenza vaccination for immunocompromised patients: summary of a systematic review and meta-analysis. Influenza Other Respir Viruses. 2013. Sep;7 Suppl 2(Suppl 2):72–75. doi: 10.1111/irv.12084. - DOI - PMC - PubMed
    1. Ram R, Hagin D, Kikozashvilli N, Freund T, Amit O, Bar-On Y, Beyar-Katz O, Shefer G, Moshiashvili MM, Karni C, Gold R, Kay S, Glait-Santar C, Eshel R, Perry C, Avivi I, Apel A, Benyamini N, Shasha D, Ben-Ami R. Safety and immunogenicity of the BNT162b2 mRNA COVID-19 vaccine in patients after allogeneic HCT or CD19-based CART therapy – A single-center prospective cohort study. Transplant Cell Ther. 2021. Sep;27(9):788–794. doi: 10.1016/j.jtct.2021.06.024. Epub 2021 Jun 30. - DOI - PMC - PubMed

Substances

LinkOut - more resources